Clinical trial · Interventional
Xray Volume Imaging (Cone Beam CT) - Prostate Cancer
A Clinical Study of X-ray Volume Imaging to Evaluate the Daily Set-up Accuracy of Conformal Prostate Radiotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Conformal dose escalated radiotherapy was adopted as the standard treatment technique at PMH for intermediate risk patients with localised disease in 1997. This technique provides a much smaller margin of error for treatment set-up and delivery than with conventional techniques. One way to ensure the accuracy of treatment delivery is to image the prostate position daily, prior to therapy, to allow for appropriate set-up corrections. To do so, imaging markers are implanted into the prostate under guided ultrasound (a standard procedure at PMH). However, there are disadvantages in using imaging markers which include added time to the treatment planning process, and an invasive procedure with a potential for discomfort, bleeding and infection. This study will investigate and compare X-ray volume imaging to the gold standard imaging markers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| daily Xray volume imaging for planning radiotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate he feasibility of daily X-ray volume imaging during conformal radiotherapy.
Secondary outcomes (1)
- measure
- To provide preliminary data concerning the relative utility of daily X-ray volume image matching compared to fiducial marker image matching.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of adenocarcinoma of the prostate * Patient undergoing escalated dose conformal external beam radiotherapy. * Patient has low or intermediate risk prognostic factors: all of PSA \<21, Gleason score \<8, clinical T category \<T3, clinical N category 0 or X, M category 0 or X. * Informed consent Exclusion Criteria: * No diagnosis of adenocarcinoma of the prostate * Patient not undergoing escalated dose conformal radiotherapy * Patient does not have low or intermediate risk prognostic factors
References
Publications (0)
Data not yet available